NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF
Nanobiotix S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$21.08−0.22 (-1.03%)
Close on Oct 19, 2026
Nanobiotix statistics
Financials through Jun 30, 2026, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Market Cap | €911.72M | €878.09M |
| Enterprise Value | €800.83M | €706.41M |
| PS Ratio | 27.97 | 6.85 |
Enterprise value
| Measure | Nanobiotix | Industry median |
|---|---|---|
| EV / Sales | 24.57 | 3.86 |
Income (trailing twelve months)
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Revenue | €32.59M | €465.66M |
| Operating Income | -€10.82M | -€54.01M |
| Pretax Income | -€23.96M | -€47.40M |
| Net Income | -€23.96M | €157.18M |
| EBITDA | -€9.32M | -€42.85M |
| EPS (Diluted) | -0.50 EUR | -0.55 EUR |
Margins
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Operating Margin | -33.2% | -33.2% |
| Pretax Margin | -73.5% | -36.6% |
| Profit Margin | -73.5% | 5.34% |
| EBITDA Margin | -28.6% | -28.6% |
| FCF Margin | -104.2% | -24.4% |
Returns
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Return on Assets (ROA) | -27.6% | -1.57% |
| Return on Capital Employed (ROCE) | -25.5% | -23.8% |
Growth
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 89.7% | 1.61% |
| Revenue Growth (5Y CAGR) | 67.0% | 14.0% |
Balance sheet
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €110.89M | €199.29M |
| Net Cash (Debt) | €110.89M | €111.50M |
| Net Cash Per Share | 2.29 EUR | 1.53 EUR |
| Working Capital | €37.55M | €119.55M |
Financial position
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Current Ratio | 1.44 | 3.49 |
| Quick Ratio | 1.31 | 1.51 |
| Interest Coverage | -0.71 | -0.71 |
Cash flow (trailing twelve months)
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Operating Cash Flow | -€33.42M | -€42.16M |
| Capital Expenditures | -€538.00K | -€2.34M |
| Free Cash Flow | -€33.96M | -€52.90M |
| FCF Per Share | -0.70 EUR | -0.48 EUR |
Efficiency
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Asset Turnover | 0.38 | 0.31 |
| Revenue Per Employee | €336.01K | €855.98K |
| Profits Per Employee | -€247.02K | -€43.26K |
| Employee Count | 97 | 304 |
Dividends and yields
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Earnings Yield | -2.63% | 1.60% |
| FCF Yield | -3.72% | -13.6% |
Shares
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Shares Outstanding | 48,410,100 | 99,540,150 |
| Shares Change (YoY) | 1.17% | 5.61% |
| Float | 48,410,100 | 78,574,400 |
| Shares Held by Insiders | 0.00% | 9.05% |
| Shares Held by Institutions | 12.0% | 13.8% |
Taxes
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Income Tax | €3.00K | €80.00K |
Scores
| Measure | Nanobiotix | Industry median |
|---|---|---|
| Altman Z-Score | 3.71 | 1.13 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from Nanobiotix's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.